Ilika PLC (AIM:IKA, OTCQX:ILIKF) saw its target price raised by Panmure Liberum after the solid-state battery developer published annual results today.
Panmure Liberum said it was a year of considerable progress for Ilika including first customer shipments of Stereax [medical] batteries from its UK pilot manufacturing facility and achieving D4 design freeze and Li-ion energy density parity in its Goliath [auto] prototypes.
Galliford Try Holdings PLC (LSE:GFRD) shares jumped by 7% as a post-close trading statement indicated revenue and pretax profit above the consensus range, helped by more normal trading conditions and the peak in AMP7 water sector work.
Based on the update, broker Panmure Liberum has increased what it said were already top-of-the-range estimates by 3% and 2% for 2024 and 2025
Shares in Faron Pharmaceuticals Limited (AIM:FARN) jumped almost 17% in early trading after receiving "very positive" feedback from the US Food & Drug Administration on the design of its phase III clinical trial for bexmarilimab, a treatment for myelodysplastic syndrome, a type of bone marrow cancer.
The FDA's feedback could streamline the development process, targeting newly diagnosed high-risk patients and eliminating the need for a separate study for resistant cases.
Ilika PLC (AIM:IKA, OTCQX:ILIKF) said it is on target for the mass adoption of solid-state battery technology after good progress in both arms of the business over the past twelve months.
In the current year, the medical division Stereax will focus on commissioning activities and engineering lots to qualify the process fully in readiness for commercial samples, production of which is expected in late 2024.
Quantum Blockchain Technologies PLC (AIM:QBT) told investors that Forcrowd Srl, an Italian crowdfunding company in which it has a 41% stake, has successfully secured registration with the European Securities and Markets Authority (ESMA).
Forcrowd has registered as an authorised provider of crowdfunding services, following a rigorous application process.
Incanthera PLC (AQSE:INC) has landed its second production order for 250,000 units with Marionnaud AG, part of the Watsons Group.
The company, which is focused on innovative technologies in dermatology, highlighted that it follows a previous increase in its first production order from 50,000 to 100,000 units, which is anticipated to generate revenues of approximately £4 million.
Graft Polymer (UK) PLC (LSE:GPL) announced the filing of two new provisional utility patent applications with the United States Patent and Trademark Office (USPTO), relating to treatments using depot drug delivery systems (DDDS) for substance use (SUDs) and mental health disorders.
One patent application addresses the use of DDDS to reduce side effects and enhance the efficacy of therapeutics used to treat SUDs.
Galliford Try Holdings PLC (LSE:GFRD) said progress has been strong in the current year, with full-year revenue and underlying profit running ahead of the top end of current market forecasts.
"We expect to report another year of strong performance across all our operations with increased revenue and profit as we continue to progress our updated Sustainable Growth Strategy to 2030,” Bill Hocking, the construction group's chief executive, said.
Faron Pharmaceuticals Limited (AIM:FARN) has received what it described as "very positive" feedback from the US Food and Drug Administration on the design of the Phase III clinical trial for its lead asset.
This feedback could significantly streamline the development process.
Ora Banda Mining Ltd (ASX:OBM) has approved the development of the Sand King Underground Mine at its 100%-owned Davyhurst Gold Project in the Eastern Goldfields of Western Australia, as it works to rapidly accelerate production and decrease costs.
The Sand King mine — the second to be developed by the company at Davyhurst in less than two years — is slated to hit a steady state production level of around 60,000 ounces per annum in the June 2025 quarter.